Brilliant Violet 421™ anti-CD105 (Endoglin)
- 产品名称：
- Brilliant Violet 421™ anti-CD105 (Endoglin)
- 产品类别：
- 抗体
- 产品编号：
- 800510
- 产品应用：
- 800510
[价格]
| 规格 |
价格 |
库存 |
| 100tests |
￥ 5852 |
1 |
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- CD105 (Endoglin) isolated from acute lymphoblastic leukemia cells.
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC -?Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application References
(PubMed link indicates BioLegend citation) -
- C Li, R Grady, BK Seon, SE Duff, S Abdalla, A Renehan, ST O'Dwyer, N Haboubi, S Kumar. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 antibody in colorectal cancer patients correlate with poor prognosis. Br J Cancer 88:1424-1431, 2003.
- Sanz-Rodriguez, Francisco, et al. Endoglin regulates cytoskeletal organization through binding to ZRP-1 a member of the Lim family of proteins. J Biol Chem 279(31):32858-68, 2004.
- Takahashi N, et al. Association of Serum Endoglin with Metastasis in Patients with Colorectal, Breast, and Other Solid Tumors, and SuppressiveEffect of Chemotherapy on the Serum Endoglin. Clin. Cancer Res.: 7(3): 524-532, Mar 2001.
- Seon BK, Matsuno F, Haruta Y, Kondo M, and Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Cancer Res.: 3(7): 1031-1044, Jul 1997.
- Haruta Y, Seon BK. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. PNAS: 83: 7898-7902, Oct 1986.
- RRID
- AB_2687062 (BioLegend Cat. No. 800509) AB_2687063 (BioLegend Cat. No. 800510)
